Should You Buy Nurix Therapeutics Inc (NRIX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
Buy now (pre-market ~17.53). NRIX is trading right on key support (S1 ~17.566) with RSI near the lower band and a heavily bullish Street setup (multiple Buy/Overweight ratings with $30–$36 targets). Despite bearish short-term momentum (negative MACD), the risk/reward favors an immediate dip-buy for an impatient buyer aiming for a rebound back toward the 18.70 pivot and potentially the 19.83 resistance if momentum turns. No politician/congress trading signal is present to contradict the thesis.
Technical Analysis
Trend/Momentum: Near-term momentum is still bearish: MACD histogram -0.19 and expanding negatively, suggesting downside pressure hasn’t fully exhausted. RSI(6) ~34.9 is close to oversold territory, which often aligns with a bounce zone rather than a fresh chase higher. Moving averages are converging, implying the prior trend is losing strength and a turn is possible but not confirmed.
Key levels: Pre-market ~17.53 is essentially at S1 (17.566). If buyers defend this zone, the first upside magnet is the pivot (18.697). Next resistance levels are R1 (19.827) and R2 (20.526). S2 sits at 16.867.
Pattern-based odds: The provided similar-candlestick study suggests modest positive drift (70% chance of +1.24% next day; +4.26% next month), consistent with a tactical dip-buy near support.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Analyst Ratings and Price Target Trends
Recent trend: Analyst sentiment has strengthened notably into late 2025 and Jan 2026 with multiple price-target raises and at least one major upgrade. Key changes include Morgan Stanley upgrading to Overweight and sharply raising PT to $36 (from $15), H.C. Wainwright raising to $32, and Mizuho/BTIG/Truist clustering around $30 Buy/Outperform.
Wall Street pros: (a) Increasing confidence in bexobrutideg’s profile in CLL, (b) platform optionality with multiple degraders entering clinic, (c) de-risking narrative from updated datasets.
Wall Street cons: JPMorgan previously cut PT to $22 (still Overweight), signaling that while the story is attractive, there is meaningful execution and trial-risk sensitivity.
Net: The balance of current analyst actions (upgrades/raises) is a clear positive and supports buying on weakness near support.
Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 28.93 USD with a low forecast of 12 USD and a high forecast of 41 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 28.93 USD with a low forecast of 12 USD and a high forecast of 41 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 17.590
Current: 17.590
